ScinoPharm Taiwan, Ltd. · TWSE:1789

ScinoPharm Taiwan — J.P. Morgan Healthcare Conference 2012

25 slides from ScinoPharm Taiwan's conference presentation, Jan 12, 2012

  1. Slide 1: ScinoPharm Management Presentation

    ScinoPharm Management Presentation TWSE 1789 Jo Shen, Ph.D. President & CEO January 12. 2012

  2. Slide 2: Disclaimer

    Confidential Disclaimer This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”). Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information cont

  3. Slide 3: Table of Content

    Confidential Table of Content Overview of ScinoPharm Financial & Operation Results Business Outlook Q&A 3

  4. Slide 4: Overview of ScinoPharm

    Overview of ScinoPharm 4

  5. Slide 5: Mission

    Confidential Mission Maintain dominant position in Specialty API for generic market Provide API custom synthesis services to new drug development & brand companies Process R&D and Clinical Supplies leading to future contract manufacturing opportunities of new chemical entities (“NCEs”) Contract Manu

  6. Slide 6: Company Overview

    Confidential Company Overview Developed more than 50 generic APIs with 16 launched Diversified technologies from small molecules to peptides & proteins State-of-the-Art facilities inspected by US FDA and authorities from Japan, Australia, Korea & EU 280+ clients, many with long-term supply agreement

  7. Slide 7: Competitive Advantages

    Confidential Competitive Advantages Heavy emphasis on R&D, with 86 patents granted worldwide to 17 inventions Combination of cost advantages from China & GMP/IP/EHS compliance in Taiwan Rich generic pipeline driven by a large & cost effective R&D infrastructure Familiarity with drug development & re

  8. Slide 8: World Class Facilities

    Confidential World Class Facilities Taiwan China 6.6 hectares of land, 330K sqft facilities With nearly 250M3 reactor volume with >200M3 reactor volume after 2 large product lines expansion The first phase completed by the end of 2011. The second phase completed by the Six of our production lines ar

  9. Slide 9: ScinoPharm Biotech

    Confidential ScinoPharm Biotech Developed lab processes for biosimilars Host systems includes E. Coli, CHO, Yeast, Insect cells Full scope development capabilities • Cloning • Expression & amplification • Fermentation & cell culture • Recovery & purification • Product characterization • Bioassay Inv

  10. Slide 10: Strong and Broad Customer Base

    Confidential Strong and Broad Customer Base Total # of customers 350 286 300 264 250 231 204 200 173 144 150 91 100 72 42 50 0 2003 2004 2005 2006 2007 2008 2009 2010 2011 10

  11. Slide 11: Strong Generics Product Portfolio

    Confidential Strong Generics Product Portfolio Focus on High Barrier and High Potency Generic API Products Type # of Product Oncological 24 CNS 6 Cardiovascular 3 Hormonal 3 Gastrointestinal 1 Muscle 3 Antiviral 3 Respiratory 1 Peptides 5 11 11

  12. Slide 12: Global DMF Filings

    Confidential Global DMF Filings Number of DMF filed 台灣神隆DMF全球註冊概覽表 台灣神隆 全球註冊概覽表 800 740 690 700 640 587 600 537 500 435 400 370 287 300 200 170 100 38 41 46 51 56 22 27 29 34 0 2006 2007 2008 2009 2010 2011 2012(E) 2013(E) 2014(E) US DMF Accumulation Worldwide DMF Accumulation ScinoPharm’s Strengths

  13. Slide 13: Major Products - Top 5 account for 66% of FY2011 sales

    Confidential Major Products-Top 5 account for 66% of FY2011 sales 2011 # of US DMF/EDMF & API Indications projected other Filings MKT Share* Docetaxel 38% Anti-Cancer 53 Anhydrous (WW) 44% Irinotecan HCI Anti-Cancer 47 (WW) 49% Galantamine HBr Alzheimer’s disease 36 (WW) 21% Paclitaxel Anti-Cancer 4

  14. Slide 14: Significant Growth of Main Products

    Significant Growth of Main Products Docetaxel Anhydrous Paclitaxel Irinotecan HCI Gemcitabine Hydrochloride Galantamine HBr 1,667 QTY(Kg) 1800 1600 1400 1200 825 689 1000 698 698 606 800 600 315 199 199 400 140 65 120 162 46 24 200 0 Y2009 Y2010 Y2011 Note: 1. Docetaxel’s launch for customer was in

  15. Slide 15: Financial & Operation Results

    Financial & Operation Results 15

  16. Slide 16: P&L (consolidated)

    P&L (consolidated) US$K, except EPS 1-3Q, ’11 1-3Q, ’10 YOY Net Sales 96,768 87,419 11% COGS (49,230) (40,563) 21% Gross Profit 47,537 46,856 1% SG&A Expense (20,553) (17,969) 14% Operating Income 26,985 28,888 -7% Non-Operating Income 1,779 1,032 72% Non-Operating Exp. (2,624) (1,925) 36% Profit be

  17. Slide 17: Balance Sheet (consolidated)

    Balance Sheet (consolidated) US$K Sept. 30, ’11 Sept. 30, ’10 Cash and Cash Equivalents 104,813 36% 50,632 23% Accounts Receivable 21,947 7% 23,420 11% Inventory 46,042 16% 41,930 19% Long-Term Investment 6,393 2% 5,043 2% Fixed Assets 101,687 35% 88,213 40% Total Assets 294,133 100% 221,150 100% Cu

  18. Slide 18: Cash Flow (consolidated)

    Cash Flow (consolidated) US$K 1-3Q, ’11 1-3Q, ’10 Cash and cash equivalents at beginning of year 62,841 23,092 Cash flows from operating activities 30,235 33,348 CAPEX (15,148) (7,407) Long-term investment - (5,043) Repayment of Long Term Loans - (29,900) Issuance of common stock 31,467 37,425 Other

  19. Slide 19: Sales by Business

    Confidential Sales by Business 2010 2011 CMO CMO 2.5% 13.4% CRO CRO 6.6% 2.4% Generic Generic 90.9% 84.2% 19

  20. Slide 20: Oncology Sales vs. Total Sales

    Confidential Oncology Sales vs. Total Sales 2010 2011 Others Others 29.6% 37.8% Oncology Oncology 70.4% 學名藥 62.2% 90.91% 20

  21. Slide 21: Sales by Region

    Confidential Sales by Region 2010 2011 ROW ROW AU & NZ 1% AU & NZ 0% 6% 6% US & CAN US & CAN 33% 38% EU EU 32% 30% Asia Asia 28% 26% 21

  22. Slide 22: Business Outlook

    Business Outlook 22

  23. Slide 23: 2012 Product Launch Plan

    2012 Product Launch Plan Regional WW Sales API Region Indications Brand Marketer Sales Argatroban Antithrombotic, $US $US US GSK Anticoagulant 139MM* 205MM* Galantamine Alzheimer’s $US $US EU Janssen HBr disease 314MM* 527MM* $US $US Modafinil US Antinarcolepsy Cephalon 1,078MM* 1,182MM* Riluzole $U

  24. Slide 24: Outlook

    Confidential Confidential Outlook Sustain Our Current Leadership Position Continue developing small molecule oncological injectable APIs and expand into other areas with high technology barriers including Peptides and Biopharmaceutical Expand Presences in China Expansion of API business to timely ca

  25. Slide 25: Brand Quality with Asian Advantages

    Confidential Brand Quality with Asian Advantages www.scinopharm.com 25

ScinoPharm Taiwan — J.P. Morgan Healthcare Conference 2012 on 6ix